Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABCL575 Single-Ascending Dose Study in Healthy Participants
NCT07108894Phase 1Active, not recruiting
- Sponsor
- AbCellera Biologics
- Start
- Jul 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing ABCL575 with Placebo (2 arms). Primary endpoints: Incidence, frequency, and severity of adverse events, Changes from baseline in laboratory parameters and 4 more. Started Jul 2025; status: active, not recruiting.
02
Drugs
ABCL575
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07108894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07108894.